Abstract
Background: Bioabsorbable polymer drug-eluting stents (BP-DES) are non-inferior to current generation DES and bare metal stents (BMS) outcomes at 12 months [ 1 Natsuaki M. et al. JACC. 2013; 62: 181-190 Crossref Scopus (186) Google Scholar , 2 Smits P.C. et al. Lancet (London. England). 2013; 381: 651-660 Google Scholar , 3 Raber L. et al. JAMA. 2012; 308: 777-787 Crossref PubMed Scopus (252) Google Scholar ]. The assumed benefit of BP-DES is to remove the polymer-triggered inflammatory stimulation associated with durable-polymer DES (DP-DES). However, potential benefits of BP-DES may require a longer follow-up period, to overcome the time taken for polymer absorption. The purpose of this meta-analysis was to compare the safety and efficacy outcomes of BP-DES over a long-term follow-up.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
